AstraZeneca Articles
Swine flu vaccine shortage likely in the USA
19 October 2009
US FDA approves AstraZeneca’s Crestor for new indication
19 October 2009
Onglyza gets 44% coverage of US commercial health plans but less than 1%of Medicare for type 2 diabetes
14 October 2009
Cancer drugs emerging as top driver of specialty drug spending
12 October 2009
Strong Ph III data on AstraZeneca/B-MS’s dapagliflozin
5 October 2009
“No Frills Drugs” push Pharma to look for a cure
30 September 2009
AstraZeneca’s Seroquel gets EU approval for bipolar recurrence
30 September 2009
US Appeals Court denies AstraZeneca in AWP case
25 September 2009
Senior management change at France’s Ipsen as Claude Bertrand joins
22 September 2009
Nektar in development deal with AstraZeneca worth over $1 billion
22 September 2009
Alcon to acquire Swiss biotech ESBATech for up to $439 million
14 September 2009
J&J decision to halt risperidone inj a setback for Alkermes’ pipeline, say analysts
1 September 2009
Zacks analysts view AstraZeneca/Forest deal favorably
18 August 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
AGI Thera terminates omeprazole deal with Axcan
14 August 2009
AstraZeneca buys rights to co-develop Forest’s ceftaroline
12 August 2009
Milestone for Seattle Genetic in MedImmune collaboration
11 August 2009
Astellas to co-promote AstraZeneca’s Symbicort in Japan
4 August 2009
AstraZeneca to progress CytoFab into Phase IIb study
30 July 2009
Abbott and AZ submit NDA for Certriad to US FDA
5 June 2009
Abbott and AZ set to co-promote TriLipix
5 June 2009
Stock Commentary - New York week to June 1, 2009
4 June 2009
Stock Commentary - Europe - week to June 1, 2009
4 June 2009
Seroquel shows strong bipolar results at APA
2 June 2009
Solvay viewing options for pharma
1 June 2009
Teva launches YouTube channel for PD
29 May 2009
Celleron licenses AZ's HDAC blocker
28 May 2009
Verus sues AZ for $1.3B over contract exit
28 May 2009
Japan on right course, says PhRMA president
27 May 2009
Retail drug sales in year to March 2009
22 May 2009
Stock Commentary - Europe - week to May 18, 2009
21 May 2009
AZ restores Toprol-XR supply
19 May 2009
Further 318 generics added to Japan's NHI list
19 May 2009
64% of BIBW 2992 patients see PR
18 May 2009
Anti-fake drug project launched in Sweden
18 May 2009
Pozen to get milestone as AZ files for PN 400
15 May 2009
Novartis names Jonathan Symonds deputy CFO
14 May 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
Japan stock market week to May 11, 2009
12 May 2009
AstraZeneca files for aspirin/esomeprazole
5 May 2009
AstraZeneca's 1st-qtr shows resiliance
30 April 2009
FDA delays AZ/B-MS Onglyza NDA review
28 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Retail drug sales in year to February 2009
24 April 2009
Stock Commentary - Europe - week to April 20, 2009
23 April 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
Court grants AstraZeneca temp injunction against Apotex
17 April 2009
Stock Commentary - Europe - week to April 13, 2009
16 April 2009
AZ eyeing up small European firms
15 April 2009
Seroquel unsafe for new indications; panel
9 April 2009
AstraZeneca OTC sale to GSK cleared in Sweden
8 April 2009
Stock Commentary - Europe - week to Aug 15
8 April 2009
FDA asks for more info on Symbicort in young
7 April 2009
Japan stock market week to April 6, 2009
7 April 2009
Retail drug sales in year to January 2009
3 April 2009
Stock Commentary - Europe - week to mar 30, 2009
2 April 2009
Solvay viewing options for pharma
2 April 2009
FDA panel backs safety of B-MS/AZ' Onglyza
2 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
New Crestor data sheds light on CV disease
2 April 2009
B-MS and AZ report dapagliflozin results
31 March 2009
FDA to discuss Seroquel sNDA in two months
31 March 2009
B-MS expands sales team in Japan
31 March 2009
US drug sales growth slows to 1.3%
30 March 2009
Stock Commentary - Europe - week to March 23, 2009
30 March 2009
BioDuro expands R&D accord with AstraZeneca
30 March 2009
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
